HelixBind

HelixBind is a private, pre-revenue diagnostics company tackling the critical global health challenge of sepsis and bloodstream infections. Its core innovation is an automated, cassette-based diagnostic platform that delivers species-level identification of over 20 pathogens, along with antimicrobial resistance markers, directly from a blood sample in approximately four hours—a dramatic improvement over the standard 2-3 day blood culture process. By providing rapid, actionable results, HelixBind aims to enable earlier, targeted antimicrobial therapy, thereby improving patient survival, combating antimicrobial resistance, and reducing healthcare costs associated with sepsis management. The company is in the development and commercialization preparation stage, actively hiring to grow its team.

Proprietary automated diagnostic platform for bloodstream infections. Integrates advanced sample preparation (handles multi-mL blood, removes inhibitory compounds and cell-free DNA), patented detection using artificial nucleic acids for multiplexed pathogen identification, and a closed-cassette system with a benchtop instrument (RaPID) to deliver species-level ID and resistance markers from whole blood in ~4 hours.

HelixBind competes in the rapid molecular diagnostics for sepsis space. Competitors include large established players like bioMérieux (BioFire FilmArray), Luminex (Verigene), and T2 Biosystems (T2Dx), as well as other startups. Differentiation hinges on HelixBind's claimed combination of high sensitivity from large blood volume, species-level ID for a broad panel, and resistance markers in a fully automated, closed system.